Press Releases - Oncology

Press Releases - Oncology

January 10, 2019
Following successful beta program, the Simoa SP-X next generation benchtop and CorPlex are launching ahead of schedule to further revolutionize cancer research, immunotherapy monitoring, and drug development
November 07, 2018
Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research
October 22, 2018
Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection
February 9, 2016
Quanterix announces that Analytical Chemistry, a leading peer-reviewed scientific journal, has published a truly groundbreaking new study authored by Dr. David Walt of Tufts University that prominently features Quanterix’s Single Molecule Array Detection technology, Simoa.     
CAMBRIDGE, MA – November 2, 2010 – Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP…
April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing. 
CAMBRIDGE, MA – May 23, 2010 – Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company’s proprietary technology that demonstrates an unprecedented sensitivity…
CAMBRIDGE, MA – October 13, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth–…
DENVER – A new test could reliably detect early increases in prostate specific antigen (PSA) levels – a biomarker commonly used to measure the recurrence of prostate cancer – in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with…